J Clin Pharmacol. 2022 Dec 16. doi: 10.1002/jcph.2192. Online ahead of print.
NO ABSTRACT
PMID:36524428 | DOI:10.1002/jcph.2192
Categories
Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy Endpoints from the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
